The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04640207|
Recruitment Status : Completed
First Posted : November 23, 2020
Last Update Posted : July 22, 2021
The study is aimed to evaluate the efficacy of the Alma Hybrid system for a new approach of facial skin treatment, using both ablative and non-ablative wavelengths.
The study will include 20 subjects with mild-moderate photodamaged skin, that will undergo 2 facial skin treatments. Follow up visit to evaluate the efficacy of the treatments will take place 1 and 3 months after the last treatment.
|Condition or disease||Intervention/treatment||Phase|
|Rejuvenation||Device: Facial skin treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective, Single-Center, Open-Label Study to Evaluate the Efficacy of the Alma Hybrid System for New Approach of Facial Skin Treatment With Minimal Downtime|
|Actual Study Start Date :||November 25, 2020|
|Actual Primary Completion Date :||July 18, 2021|
|Actual Study Completion Date :||July 18, 2021|
Experimental: Facial skin treatment
Facial skin treatment using the Alma Hybrid system.
Device: Facial skin treatment
Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
- Investigator assessment [ Time Frame: 3 month after last treatment ]Investigator assessment of the overall facial skin aesthetic appearance using a 5 point Likert scale (when "1" indicate "not at all improved" and "5" indicates " very much improved"
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04640207
|United States, Pennsylvania|
|Dermatology Associates of Plymouth Meeting, P.C.|
|Plymouth Meeting, Pennsylvania, United States, 19762|
|Principal Investigator:||Thomas Griffin, MD||Dermatology Associates of Plymouth Meeting, P.C.|